Biosolution Co.Ltd Asset Resilience Ratio
Biosolution Co.Ltd asset resilience ratio. Biosolution Co.Ltd (086820) has an Asset Resilience Ratio of 0.34% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Biosolution Co.Ltd (086820) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biosolution Co.Ltd (2015–2024)
Asset resilience ratio of Biosolution Co.Ltd from 2015 to 2024. This chart shows how Biosolution Co.Ltd's Asset Resilience Ratio has changed over time. Read Biosolution Co.Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biosolution Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Biosolution Co.Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩211.66 Million | 0.34% |
| Total Liquid Assets | ₩211.66 Million | 0.34% |
Asset Resilience Insights
- Limited Liquidity: Biosolution Co.Ltd maintains only 0.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biosolution Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Biosolution Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Biosolution Co.Ltd Asset Resilience Ratio by Year (2015–2024)
Biosolution Co.Ltd asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Biosolution Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.27% | ₩14.35 Billion ≈ $9.72 Million |
₩67.46 Billion ≈ $45.72 Million |
-19.56pp |
| 2023-12-31 | 40.83% | ₩37.71 Billion ≈ $25.56 Million |
₩92.35 Billion ≈ $62.58 Million |
-38.53pp |
| 2022-12-31 | 79.36% | ₩72.80 Billion ≈ $49.34 Million |
₩91.73 Billion ≈ $62.16 Million |
-8.65pp |
| 2021-12-31 | 88.01% | ₩83.08 Billion ≈ $56.30 Million |
₩94.40 Billion ≈ $63.98 Million |
+15.31pp |
| 2020-12-31 | 72.70% | ₩36.20 Billion ≈ $24.54 Million |
₩49.80 Billion ≈ $33.75 Million |
-5.43pp |
| 2019-12-31 | 78.13% | ₩40.48 Billion ≈ $27.43 Million |
₩51.81 Billion ≈ $35.11 Million |
-6.71pp |
| 2018-12-31 | 84.85% | ₩44.85 Billion ≈ $30.40 Million |
₩52.87 Billion ≈ $35.83 Million |
+54.06pp |
| 2017-12-31 | 30.79% | ₩2.27 Billion ≈ $1.54 Million |
₩7.38 Billion ≈ $5.00 Million |
+1.51pp |
| 2016-12-31 | 29.27% | ₩2.58 Billion ≈ $1.75 Million |
₩8.82 Billion ≈ $5.98 Million |
-1.40pp |
| 2015-12-31 | 30.67% | ₩3.01 Billion ≈ $2.04 Million |
₩9.80 Billion ≈ $6.64 Million |
-- |
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more